How is coronavirus SARS-COV-2 infection diagnosed?

Reading time: 2 min

The diagnosis of any disease depends on the history as well as the set of symptoms and signs presented by the patient, taking into account the epidemiological situation and other data interpreted by the medical team.

When dealing with infectious diseases it is very important to have tests that quickly identify which microorganism is responsible for the infection. This allows decisions to be made on the most appropriate treatment and management.

The following tests can be used to diagnose COVID-19, particularly in high-risk patients:

DNA molecule or helix

Polymerase chain reaction (PCR): This is considered the reference test for molecular diagnosis. However, the test has limitations, with the quality of the sample obtained from a nasal or pharyngeal swab being critical.

The test is used to confirm an active infection, generally a few days after exposure, when symptoms typically begin. PCR test results may be negative in the early stages of infection, which can provide a false sense of security. In addition, it may yield a positive result, despite the absence of viable (infectious) virus, particularly toward the end of the illness.

Image showing a vial and the instrument for taking the sample and do the antigen test

Rapid antigen tests (RATs): These detect viral proteins. They are simpler, faster and less expensive than PCR tests, although less sensitive. They perform best when the viral load is highest—that is, when the person is in the most infectious phase of the disease.

Sample tube and antibodies for Ro (or SS-A) and La (or SS-B) test

Antibody tests. These tests are not used to diagnose an active COVID-19 infection. They can determine if a person had a previous infection, even if it was asymptomatic.

Diferencia entre PCR y test rápido ...

Substantiated information by:

Published: 12 March 2020
Updated: 17 December 2024

The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.

Subscribe

Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.